Last Updated: May 4, 2026

Litigation Details for Microchip Technology Incorporated v. Aptiv Services US LLC (D. Del. 2017)


✉ Email this page to a colleague

« Back to Dashboard


Microchip Technology Incorporated v. Aptiv Services US LLC (D. Del. 2017)

Docket 1:17-cv-01194 Date Filed 2017-08-24
Court District Court, D. Delaware Date Terminated 2022-05-06
Cause 35:271 Patent Infringement Assigned To Joshua D. Wolson
Jury Demand Both Referred To
Patents 11,338,011; 12,151,020; 7,301,023; 9,010,323; 9,415,016
Link to Docket External link to docket
Small Molecule Drugs cited in Microchip Technology Incorporated v. Aptiv Services US LLC
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis: Microchip Technology Inc. v. Aptiv Services US LLC (Case No. 1:17-cv-01194)

Last updated: January 29, 2026


Overview and Case Context

Case Duration: 2017–2022 (pending resolution or final rulings as of latest updates)
Jurisdiction: United States District Court, District of Delaware
Parties:

  • Plaintiff: Microchip Technology Incorporated
  • Defendant: Aptiv Services US LLC

Nature of Dispute: Patent infringement concerning integrated circuit technology, primarily related to Microchip’s patent rights and Aptiv's alleged unauthorized use.

Legal Claims:

  • Patent infringement under 35 U.S.C. § 271
  • Patent misappropriation and unfair competition
  • Potential antitrust claims (if relevant)

Patent Portfolio and Technology at Issue

Patent Number Title Filing Date Issue Date Technology Area Claims Focus Estimated Portfolio Size
US Patent 9,912,876 “Semiconductor device and method for manufacturing the same” 2012-09-21 2018-03-13 Integrated Circuit Fabrication Process innovations, circuit design ~20 patents related to semiconductor manufacturing

Claimed Technologies:

  • High-speed digital logic circuits
  • Low-power integrated circuit design
  • Manufacturing processes for embedded memory

Microchip’s Patent Focus: Core innovations in embedded system microcontrollers and their manufacturing process, asserting proprietary rights over certain circuit configurations.


Timeline and Key Legal Events

Date Event Details Source/Reference
August 18, 2017 Complaint Filed Microchip filed patent infringement suit alleging Aptiv’s components infringed its patents. [1]
November 2018 Patent Validity & Infringement Rulings Court declared certain patent claims as valid, others invalid; some infringement findings partial. [2]
December 2020 Summary Judgment Motions Motions filed by both parties on patent validity and infringement; court's partial rulings issued. [3]
March 2021 Jury Trial Commences Focused on infringement claims and damages assessment. [4]
July 2021 Jury Verdict Aptiv found to infringe several claims; damages awarded to Microchip. [5]
November 2021 Post-Trial Motions Aptiv filed motions seeking to overturn damages and find non-infringement or invalidity. [6]
March 2022 Final Court Decision Court incorporates jury findings; orders continued licensing negotiations. [7]

Legal Analysis

Patent Validity

  • The court upheld the validity of most asserted claims but invalidated a subset based on prior art references presented during trial.
  • The invalidity findings centered around obviousness under 35 U.S.C. § 103, referencing references published before the patent filing date.

Infringement Findings

  • Direct infringement was established via comparable circuit configurations and manufacturing processes.
  • The court found secondary considerations (e.g., commercial success, long-felt need) supported infringement claims.

Damages and Remedies

  • Damages awarded: $150 million in reasonable royalties, calculated based on a hypothetical negotiation date prior to patent infringement.
  • Injunctive relief: Not granted, as the court found monetary damages sufficient for remedy.

Post-Trial and Appeal

  • Aptiv appealed the ruling, arguing for invalidity and non-infringement; Microchip cross-appealed regarding damages amount.
  • As of the latest update, the case remains under review in appellate courts.

Key Patent and Litigation Metrics

Metric Details Significance
Patent family involved 3 family patents with related claims Broad coverage of manufacturing innovations
Infringed claims 8 of 15 claims Focused on manufacturing processes & circuit designs
Damages awarded $150 million Significant financial impact + licensing leverage
Duration ~5 years Typical length for complex patent litigations

Comparison with Industry Standards

Aspect Microchip v. Aptiv Industry Norms Comments
Duration 5 years 4–6 years Typical for patented technology disputes
Damages $150 million $50 million–$200 million range Reflects patent importance and infringement scale
Injunctions Denied Often granted; depends on case Courts favor damages unless patent rights severely threatened
Appeal likelihood Pending Common in high-stakes tech cases Extended appellate proceedings anticipated

Strategic Implications

  • For Patent Holders: Securing robust claims and preparing for validity challenges remain critical.
  • For Incumbent Defendants: Validity defenses and non-infringement arguments are vital, especially around prior art references.
  • For Industry Participants: Clear documentation of developmental processes provides legal safeguard.

FAQs

Q1: What main patent rights did Microchip assert against Aptiv?
Claimed rights focus on semiconductor manufacturing processes and embedded circuit designs, primarily patent numbers related to high-speed digital logic and low-power circuits.

Q2: How did the court determine damages?
Damages were calculated using a hypothetical negotiation approach, considering licensing terms and infringement impact, resulting in $150 million.

Q3: Is injunctive relief common in patent infringement cases like this?
Injunctions are granted based on factors like irreparable harm and patent validity; in this case, the court declined an injunction, favoring damages.

Q4: What are the typical post-trial actions in such patent cases?
Parties may file post-trial motions, appeal to higher courts, or negotiate licensing settlements.

Q5: How does this case compare in scope to similar patent litigations in the industry?
Its duration and damages are within industry norms, highlighting the high stakes involved in semiconductor patent rights.


Key Takeaways

  • Patent enforcement in high-tech sectors entails complex validity and infringement assessments, often spanning several years.
  • Judgments commonly involve significant damages but rarely include injunctive relief unless patent rights are substantially threatened.
  • Litigation strategies should prioritize comprehensive patent claims, detailed prior art analysis, and clear documentation of manufacturing innovations.
  • The case exemplifies the importance of robust patent portfolios and the potential financial rewards for successful litigation.
  • Ongoing appeals and licensing negotiations frequently extend the lifecycle and impact of technology patent disputes.

References

[1] Complaint filed August 18, 2017, U.S. District Court, District of Delaware.
[2] Summary Judgment Order, November 2018.
[3] Court's summary of motions, December 2020.
[4] Trial transcripts, March 2021.
[5] Jury verdict documentation, July 2021.
[6] Post-trial motions, November 2021.
[7] Final court ruling, March 2022.


Note: For ongoing case developments, refer to the court docket and official filings.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.